Regulatory T cells (Treg) play a role in suppression of anti-melanoma immunity; however, the exact mechanism is poorly understood. Through intravital two photon microscopy, we found that Pmel-1 effectors engage in cell-cell interactions with tumor resident Tregs. To determine if contact between Tregs and T effectors (Teff) hinders killing of tumor cells in vivo, we utilized ex-vivo three-dimensional collagen-fibrin gel cultures of B16 melanoma cells. Collagen-fibrin gel cultures recapitulated the in vivo suppression, rendering the dissociated tumor resistant to killing by in vitro activated antigen specific Teff. In vivo depletion of Tregs in foxp3-DTR mice prior to tumor excision reversed the suppression. Additionally, In vivo modulation of intra-tumor Tregs suppressive function by GITR ligation had a similar effect, leading to ex-vivo tumor killing. Using neutralizing antibodies, we found that blocking TGF-β reversed the suppression. In addition, soluble factors from collagen-fibrin gel tumors do not inhibit killing suggesting that suppression is contact or proximity dependent. The CD8 Teff recovered from these gels exhibit a decrease in Granzyme B expression and an increase in expression of T cell exhaustion marker PD-1. These findings support the conclusion that intra-tumor contact with Tregs during the effector phase of the immune response is responsible for inhibiting anti-melanoma immunity in a TGF-β dependent manner, elucidating a novel way to target intratumoral Tregs.
. 2013 Nov 7;1(Suppl 1):P173. doi: 10.1186/2051-1426-1-S1-P173
Blockade of Treg derived TGF-β abrogates suppression of effector T cell function within the tumor microenvironment
Sadna Budhu
1, David Schaer
1,✉, Yongbiao Li
1, Alan Houghton
1, Samuel Silverstein
3, Taha Merghoub
1,2, Jedd Wolchok
1,2
Taha Merghoub
1Immunology, MSKCC, New York, NY, USA
2Medicine, MSKCC, New York, NY, USA
Find articles by Taha Merghoub
Jedd Wolchok
1Immunology, MSKCC, New York, NY, USA
2Medicine, MSKCC, New York, NY, USA
Find articles by Jedd Wolchok
1Immunology, MSKCC, New York, NY, USA
2Medicine, MSKCC, New York, NY, USA
3Columbia University, New York, NY, USA
✉
Corresponding author.
Supplement
Abstracts of the 28th Annual Scientific Meeting of the Society for Immunotherapy of Cancer (SITC)
Carl Ruby
This supplement has not been sponsored. The Supplement Editor declares that he has no competing interests.
Conference
8-10 November 2013
Society for Immunotherapy of Cancer 28th Annual Meeting
National Harbor, MD, USA
Collection date 2013.
Copyright © 2013 Budhu et al; licensee BioMed Central Ltd.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
PMCID: PMC3990987
